IPH4502 Phase 1 Clinical Trial for Solid Tumors Expressing Nectin-4
/in Clinical Trial, Metastatic, Phase 1/by MaxModified Virus Shows Promise in Shrinking Tumors and Halting Cancer Growth
/in Not PCa related/by MaxWe can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by MaxNewsletter 3/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi, fellow fighters! Ok, this week I had to take some time off for my PET scan and checkup, so I haven’t gathered as much information as usual to share with you. Nonetheless, what I found is still very interesting and promising! […]
Update on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/in Clinical Trial, Metastatic, Phase 1/by MaxUMass Scientists Develop Novel Bacteria-Based Cancer Therapy
/in Oncolytic, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026